RIBOMIC Inc. is engaged in the drug discovery business based on the platform Ribomic Aptamer Refined Therapeutics System related to aptamer drug discovery technology. Its drug discovery business is divided into self discovery and co-discovery divisions. Self Drug Discovery division develops aptamer and licenses and out the results to pharmaceutical companies. The Co-Discovery division earns the research expenses paid by the alliance partner for the shared part of co-discovery business with alliance pharmaceutical companies researching aptamer pharmaceutical.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
17/06/26	62.00 ¥	+5.08%	1,080,600
16/06/26	59.00 ¥	-4.84%	879,700
15/06/26	62.00 ¥	-1.59%	155,300
12/06/26	63.00 ¥	+1.61%	546,600
11/06/26	62.00 ¥	0.00%	303,100

Delayed Quote Japan Exchange

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Closed - Japan Exchange Other stock markets 07:30:00 17/06/2026 BST			5-day change	1st Jan Change
62.00 ^JPY	+5.08%		0.00%	-20.51%

03-19	Ribomic Files IND For Phase III Trial Of Achondroplasia Drug In Japan	MT
03-19	Ribomic Inc Announces IND Application for Phase III Clinical Trial of Umedaptanib Pegol for Achondroplasia Treatment	CI

Market Cap	4.78B 29.83M 25.73M 23.66M 22.27M 41.84M 2.81B 42.19M 280M 109M 1.38B 112M 110M	P/E 2024	-3.24x	P/E 2025	-3.89x
Enterprise Value	1.74B 10.87M 9.38M 8.62M 8.12M 15.25M 1.03B 15.38M 102M 39.79M 504M 40.81M 39.94M	EV / Sales 2024	-	EV / Sales 2025	666x
Free-Float	96.31%	Yield 2024 *	-	Yield 2025	-

03-19	Ribomic Files IND For Phase III Trial Of Achondroplasia Drug In Japan	MT
03-19	Ribomic Inc Announces IND Application for Phase III Clinical Trial of Umedaptanib Pegol for Achondroplasia Treatment	CI
03-10	Ribomic Reports Positive Phase II Results For Achondroplasia Drug	MT
03-10	Ribomic, Inc. Announces Summary Report on Primary Endpoint for Phase Ii Clinical Trial of Umedaptanib Pegol in the Treatment of Achondroplasia	CI
02-12	Ribomic Inc. Reports Earnings Results for the Nine Months Ended December 31, 2025	CI
01-14	Ribomic Files Patent for Anti-Autotaxin Aptamer RBM-006	MT
01-14	RIBOMIC, Inc. Announces New Substance Patent Application for Highly Active RBM-006 (Anti-Autotaxin Aptamer) and its Drug Impact in a Mouse Model of Diabetic Retinopathy	CI
11-21	Ribomic Shows Sustained Two-Year Gains in Achondroplasia Trial	MT
07/10/25	Ribomic Reports Positive Phase 2 Results for Achondroplasia Drug Umedaptanib Pegol	MT
07/10/25	Ribomic, Inc. Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of Up to +5.0 Cm/Year with Biweekly Administration in Children Aged 5 Years and Older	CI
07/10/25	Ribomic announces positive phase 2 cohort 2 results for umedaptanib pegol in achondroplasia	RE
25/09/25	Ribibo, Inc. Announces Discovery of Therapeutic Effects of Umedaptanib Pegol in A Diabetic Retinopathy Model and New Patent Application for Use	CI
20/08/25	Ribomic Reports Sustained Efficacy of Achondroplasia Drug in Long-Term Trial	MT

07/10/25	RIBOMIC Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of up to +5.0 cm/year with Biweekly Administration in Children Aged 5 Years and Older	BU
05/11/24	RIBOMIC Announces Positive Interim Results from Phase IIa Trial of umedaptanib pegol in Achondroplasia Demonstrating Increase in Annualized Growth Rate of up to +4.6 cm/year in Children 5 Years of Age and Older in the Low Dose Cohort	BU
03/08/24	RIBOMIC Announces Completion of Patient Enrollment in Early Phase II Study of umedaptanib pegol for Achondroplasia and Initiation of Dosing in Cohort 2 of Early Phase II Clinical Study	BU
05/12/23	RIBOMIC Phase I and II Data Published in the Eye: Full TOFU/RAMEN/TEMPURA Trial Results Demonstrate Clinical Proof of Concept of Umedaptanib Pegol in Exudative Age-Related Macular Degeneration (nAMD)	BU
29/07/22	RIBOMIC : Announces Issuance of US Patent for its RBM-010, Novel Drug Candidate for Osteoarthritis	PU

Ribomic Inc. Share Price

Stocks

4591

JP3974850004

Biotechnology & Medical Research

Valuation: Ribomic Inc.

Chart: Ribomic Inc.

Latest news : Ribomic Inc.

Press Releases: Ribomic Inc.

News in other languages: Ribomic Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Ribomic Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

08/10/25	RIBOMIC veröffentlicht positive Ergebnisse der Phase-2-Kohorte 2 für Umedaptanib Pegol bei Achondroplasie, die eine Steigerung der annualisierten Wachstumsrate um bis zu +5,0 cm/Jahr bei zweiwöchentlicher Verabreichung bei Kindern ab 5 Jahren zeigen
06/11/24	RIBOMIC gibt positive Zwischenergebnisse der Phase-IIa-Studie mit Umedaptanib Pegol bei Achondroplasie bekannt, die eine Steigerung der annualisierten Wachstumsrate von bis zu +4,6 cm/Jahr bei Kindern ab 5 Jahren in der niedrig dosierten...
20/02/20	RIBOMIC : kündigt erste Injektion in der klinischen Phase-2-Studie von RBM-007 (TOFU-Studie) bei Patienten mit feuchter altersbedingter Makula-Degeneration an
19/06/19	RIBOMIC : gibt positive Topline-Ergebnisse der klinischen Phase-1/2a-Studie an RBM-007 (SUSHI-Studie) bei Patienten mit feuchter altersbedingter Makuladegeneration bekannt

1 day	+5.08%
Current month	-11.43%
1 month	-17.33%
3 months	-37.37%
6 months	-19.48%
Current year	-20.51%

1 week	57	64
1 month	57	80
Current year	57	120
1 year	57	141
3 years	57	170
5 years	57	944
10 years	57	1,109

Manager	Title	Age	Since
Yoshikazu Nakamura PSD	President	78	31/03/2012
Toshiya Imai DFI	Director of Finance/CFO	-	-
Takeo Adachi CTO	Chief Tech/Sci/R&D Officer	38	30/09/2023

Director	Title	Age	Since
Toshiaki Nishihata BRD	Director/Board Member	77	31/05/2016
Yoshikazu Nakamura BRD	Director/Board Member	78	30/09/2005
Hisato Oiwa BRD	Director/Board Member	68	31/05/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RIBOMIC INC.	+5.08%	0.00%	-31.87%	-61.25%	20.24M
ARGENX SE	+3.23%	+2.93%	+61.50%	+113.87%	54.54B
WUXI APPTEC CO., LTD.	+0.04%	+5.05%	+43.44%	+36.75%	43.86B
BIONTECH SE	+3.04%	+6.61%	-13.27%	-18.06%	22.63B
INSMED INCORPORATED	+3.07%	-0.60%	-3.09%	+392.25%	20.7B
WUXI BIOLOGICS (CAYMAN) INC.	-0.53%	-0.27%	+12.68%	-37.07%	15.84B
GENMAB A/S	+5.27%	+1.71%	+11.09%	-38.81%	14.83B
EXELIXIS, INC.	+0.65%	-1.04%	+25.60%	+174.70%	13.1B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-5.17%	+4.13%	+13.12%	-	12.66B
MADRIGAL PHARMACEUTICALS, INC.	-0.27%	+4.82%	+75.35%	+104.79%	11.56B
Average	+1.44%	-0.32%	+19.46%	+74.13%	20.97B
Weighted average by Cap.	+1.53%	+0.18%	+31.62%	+90.67%

	2024	2025
Net sales	-	2M 12.48K 10.77K 9.9K 9.32K 17.51K 1.18M 17.66K 117K 45.68K 578K 46.85K 45.85K
Net income	-1.02B -6.39M -5.51M -5.07M -4.77M -8.97M -603M -9.04M -60.07M -23.39M -296M -23.99M -23.47M	-1.02B -6.35M -5.48M -5.04M -4.74M -8.91M -600M -8.99M -59.72M -23.25M -294M -23.85M -23.34M
Net Debt	-3.4B -21.21M -18.3M -16.83M -15.84M -29.76M -2B -30.01M -199M -77.63M -983M -79.62M -77.92M	-3.04B -18.95M -16.35M -15.03M -14.15M -26.59M -1.79B -26.81M -178M -69.36M -878M -71.14M -69.62M